Short Bowel Syndrome Clinical Trial
— EASE SBS 3Official title:
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial
| Verified date | November 2023 |
| Source | Zealand Pharma |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.
| Status | Enrolling by invitation |
| Enrollment | 129 |
| Est. completion date | April 2025 |
| Est. primary completion date | April 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 90 Years |
| Eligibility | Inclusion Criteria: - Informed consent obtained before any trial-related activity - Completed the full treatment period of the extension trial EASE SBS 2 (ZP1848-17127) Exclusion Criteria: - Any condition, disease, or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or confound the planned assessments of the trial - Not having a colonoscopy performed at End of Trial in EASE SBS 2 (for patients with remnant colon). Note. The results of the colonoscopy must not give rise to any safety concerns. A colonoscopy performed within 6 months prior to End of Trial and not giving rise to any safety concerns is accepted. For patients with a remnant colon, which is not connected to the passage of foods and is thereby dormant, a computerized tomography (CT) scan or magnetic resonance imaging (MRI) will suffice at the discretion of the Investigator - Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP-4) inhibitors, somatostatin, or analogs thereof within 3 months. Note: Prior use of glepaglutide trial drug is allowed - Females of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant, or are not using highly effective contraceptive methods |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Universitair Ziekenhuis Leuven | Leuven | |
| Denmark | Rigshospitalet | Copenhagen | |
| France | Hôpital Beaujon | Clichy | |
| France | Centre Hospitalier Lyon-Sud | Pierre-Bénite | |
| Germany | Charité - Universitätsmedizin Berlin | Berlin | |
| Germany | Universitätsklinikum Bonn | Bonn | |
| Germany | Universitätsklinikum Frankfurt | Frankfurt | |
| Germany | Asklepios Kliniken Hamburg GmbH | Hamburg | |
| Germany | Universitätsmedizin Rostock | Rostock | |
| Netherlands | UMC Radboud Nijmegen | Nijmegen | |
| Poland | Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi | Lódz | |
| Poland | Szpital Skawina sp. z o.o. im. Stanley Dudricka | Skawina | |
| United Kingdom | St Mark's Hospital | Harrow | |
| United Kingdom | UCLH Foundation NHS Trust | London | |
| United Kingdom | Norfolk and Norwich University Hospitals | Norwich | |
| United States | Vanderbilt University Medical Center, Nashville | Nashville | Tennessee |
| United States | University of Nebraska Medical Center | Omaha | Nebraska |
| United States | Mayo Clinic College of Medicin | Rochester | Minnesota |
| United States | Georgetown University Medical Center | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| Zealand Pharma |
United States, Belgium, Denmark, France, Germany, Netherlands, Poland, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence and type of Adverse Events (AEs) | For AEs with onset or worsening following Visit 1 | After 108 weeks | |
| Secondary | Incidence and type of Serious Adverse Events (SAEs) | For AEs with onset or worsening following Visit 1 | After 108 weeks | |
| Secondary | Incidence and type of Adverse Events of Special Interest (AESIs) | For AEs with onset or worsening following Visit 1 | After 108 weeks | |
| Secondary | Change in body temperature | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in heart rate | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in blood pressure | Seated diastolic and systolic blood pressure | Week 0 in lead-in trial (EASE SBS 1), Week 108 | |
| Secondary | Change in body weight | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Number of participants with clinically significant changes in 12-Lead electrocardiogram (ECG) | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in hematology - hemoglobin | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in hematology - hematocrit | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in hematology - white blood cell count | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in hematology - platelet count | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - sodium | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - potassium | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - chloride | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - bicarbonate | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - blood urea nitrogen | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - creatinine | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - creatinine clearance | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - glucose | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - calcium | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - phosphorous | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - alkaline phosphatase | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - alanine aminotransferase (ALT) | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - aspartate aminotransferase (AST) | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - International Normalized Ratio (INR) | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - gamma-glutamyl transferase (GGT) | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - lactic dehydrogenase | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - conjugated bilirubin | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - total bilirubin | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - total protein | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - albumin | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - amylase | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - uric acid | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in biochemistry - C-reactive protein | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - blood | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - glucose | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - leukocytes | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - pH | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - osmolality | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - protein | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - sodium | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Change in urinalysis - potassium | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Anti-glepaglutide antibodies | Week 0, Week 108 | ||
| Secondary | Antibody reactivity to ZP1848 | Week 0, Week 108 | ||
| Secondary | Cross-reactivity to glucagon-like peptide-2 (GLP-2) | Week 0, Week 108 | ||
| Secondary | Glepaglutide neutralizing antibodies | Week 0, Week 108 | ||
| Secondary | Reduction in weekly Parenteral Support (PS) volume | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Reduction of at least 20 percent in weekly PS volume | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Reduction in days on PS greater than or equal to 1 day per week | Week 0 in lead-in trial (EASE SBS 1), Week 108 | ||
| Secondary | Reduction in weekly PS volume of 100 percent (weaned off) | Week 0 in lead-in trial (EASE SBS 1), Week 108 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05635747 -
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
|
||
| Completed |
NCT01891279 -
Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?
|
N/A | |
| Completed |
NCT00930644 -
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
|
Phase 3 | |
| Completed |
NCT01696656 -
Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency
|
N/A | |
| Completed |
NCT00910104 -
Cholestasis Reversal: Efficacy of IV Fish Oil
|
Phase 2/Phase 3 | |
| Completed |
NCT04981262 -
Improved Quality of Life in Children With Intestinal Failure
|
N/A | |
| Completed |
NCT01930539 -
Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
|
N/A | |
| Recruiting |
NCT05023382 -
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
|
||
| Recruiting |
NCT04733066 -
Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
|
||
| Terminated |
NCT00742157 -
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
|
Phase 4 | |
| Completed |
NCT04743960 -
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
|
N/A | |
| Completed |
NCT03690206 -
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
|
Phase 3 | |
| Terminated |
NCT02266849 -
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
|
Phase 3 | |
| Completed |
NCT01306838 -
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
|
Early Phase 1 | |
| Completed |
NCT01380366 -
rHGH and Intestinal Permeability in Intestinal Failure
|
Phase 4 | |
| Completed |
NCT00248573 -
Mechanisms of Adaptation in Human Short Bowel Syndrome
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03371862 -
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
|
Phase 2 | |
| Completed |
NCT04474743 -
Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
|
||
| Completed |
NCT00067860 -
Diet/Growth Factor Mechanisms of Gut Adaptation
|
Phase 2 | |
| Terminated |
NCT04046328 -
Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
|
Phase 2 |